Here are the major publications from ours researchers

  • 2022
    1. Agniel D, Hejblum BP, Thiebaut R, Parast L. Doubly robust evaluation of high-dimensional surrogate markers. Biostatistics. 2022.
    2. Aicher SM, Streicher F, Chazal M, Planas D, Luo D, Buchrieser J, et al. Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. Journal of virology. 2022;96(14):e0060822.
    3. Alexandre M, Marlin R, Prague M, Coleon S, Kahlaoui N, Cardinaud S, et al. Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. Elife. 2022;11.
    4. Anywaine Z, Barry H, Anzala O, Mutua G, Sirima SB, Eholie S, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 2022;19(1):e1003865.
    5. Benotmane I, Bruel T, Planas D, Fafi-Kremer S, Schwartz O, Caillard S. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney Int. 2022;101(5):1073-6.
    6. Boudhabhay I, Serris A, Servais A, Planas D, Hummel A, Guery B, et al. COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrol Dial Transplant. 2022;37(7):1357-65.
    7. Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nature medicine. 2022;28(6):1297-302.
    8. Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, et al. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine. 2022;51:101576.
    9. Ceglia V, Zurawski S, Montes M, Kroll M, Bouteau A, Wang Z, et al. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines. Frontiers in immunology. 2022;12:786144.
    10. Coleon S, Wiedemann A, Surenaud M, Lacabaratz C, Hue S, Prague M, et al. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine. 2022;80:104062.
    11. Deplanque D, Cviklinski S, Bardou M, Ader F, Blanchard H, Barthelemy P, et al. Health crisis: What opportunities for clinical drug research? Therapie. 2022;77(1):59-67.
    12. Dufloo J, Planchais C, Fremont S, Lorin V, Guivel-Benhassine F, Stefic K, et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nature communications. 2022;13(1):630.
    13. Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, et al. Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years. Scientific reports. 2022;12(1):20373.
    14. Fenwick C, Turelli P, Ni D, Perez L, Lau K, Herate C, et al. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. Nat Microbiol. 2022;7(9):1376-89.
    15. Gallais F, Gantner P, Planas D, Solis M, Bruel T, Pierre F, et al. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. Frontiers in immunology. 2022;13:790212.
    16. Galmiche S, Fernandes-Pellerin S, Ungeheuer MN, Schwartz O, Attia M, Hoen B, et al. High negative predictive value of RT-PCR in patients with high likelihood of SARS-CoV-2 infection. Infect Dis Now. 2022;52(1):52-3.
    17. Hadjadj J, Planas D, Ouedrani A, Buffier S, Delage L, Nguyen Y, et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022;81(5):720-8.
    18. Henriquez S, Zerbit J, Bruel T, Ouedrani A, Planas D, Deschamps P, et al. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. Blood. 2022;139(6):942-6.
    19. Klingler J, Paul N, Laumond G, Schmidt S, Mayr LM, Decoville T, et al. Distinct antibody profiles in HLA-B *57+, HLA-B *57- HIV controllers and chronic progressors. Aids. 2022;36(4):487-99.
    20. Lin LY, Carapito R, Su B, Moog C. Fc receptors and the diversity of antibody responses to HIV infection and vaccination. Genes Immun. 2022;23(5):149-56.
    21. Lorin V, Fernandez I, Masse-Ranson G, Bouvin-Pley M, Molinos-Albert LM, Planchais C, et al. Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. The Journal of experimental medicine. 2022;219(3).
    22. Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, et al. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022.
    23. Lucas J, Lin LY, Paul N, Laumond G, Klingler J, Schmidt S, et al. Identification of early-induced broadly neutralizing activities against transmitted founder HIV strains. Aids. 2022.
    24. Molino D, Durier C, Radenne A, Desaint C, Ropers J, Courcier S, et al. A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project. Nature medicine. 2022;28(5):882-4.
    25. Morel A, Imbeaud S, Scemla A, Pere H, Fourgeaud J, Amrouche L, et al. Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. Am J Transplant. 2022;22(8):2099-103.
    26. Pastor Y, Ghazzaui N, Hammoudi A, Centlivre M, Cardinaud S, Levy Y. Refining the DC-targeting vaccination for preventing emerging infectious diseases. Frontiers in immunology. 2022;13:949779.
    27. Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. bioRxiv. 2022.
    28. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671-5.
    29. Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med (N Y). 2022.
    30. Prague M, Alexandre M, Thiebaut R, Guedj J. Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission? Anaesth Crit Care Pain Med. 2022;41(2):101055.
    31. Prague M, Lavielle M. SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models. CPT Pharmacometrics Syst Pharmacol. 2022;11(2):161-72.
    32. Richert L, Lelievre JD, Lacabaratz C, Hardel L, Hocini H, Wiedemann A, et al. T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. Journal of immunology. 2022;208(12):2663-74.
    33. Russo E, Lemaitre F, Corre B, Chikina AS, Langa-Vives F, Bousso P. SPICE-Met: profiling and imaging energy metabolism at the single-cell level using a fluorescent reporter mouse. The EMBO journal. 2022;41(19):e111528.
    34. Saunders N, Planas D, Bolland WH, Rodriguez C, Fourati S, Buchrieser J, et al. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. EBioMedicine. 2022;77:103934.
    35. Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? Nature reviews Microbiology. 2022.
    36. Tariq M, Gallien S, Surenaud M, Wiedemann A, Jean-Louis F, Lacabaratz C, et al. Profound Defect of Amphiregulin Secretion by Regulatory T Cells in the Gut of HIV-Treated Patients. Journal of immunology. 2022;208(10):2300-8.
    37. Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, et al. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(20):e2120976119.
    38. Vo HTM, Maestri A, Auerswald H, Sorn S, Lay S, Seng H, et al. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort. Frontiers in immunology. 2022;13:817905.
    39. Wagstaffe HR, Anzala O, Kibuuka H, Anywaine Z, Sirima SB, Thiebaut R, et al. NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. Vaccines. 2022;10(6).
    40. Wiedemann A, Pellaton C, Dekeyser M, Guillaumat L, Dechenaud M, Krief C, et al. Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. Front Med (Lausanne). 2022;9:978764.
    41. Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, et al. A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022;375(6580):540-5.
  • 2021
    1. Alexandre M, Prague M, Thiebaut R. Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Stat Methods Med Res. 2021;30(9):2130-47.
    2. Altman MC, Rinchai D, Baldwin N, Toufiq M, Whalen E, Garand M, et al. Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature communications. 2021;12(1):4385.
    3. Annane D, Godot V. Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2. Critical care medicine. 2021.
    4. Armani-Tourret M, Zhou Z, Gasser R, Staropoli I, Cantaloube-Ferrieu V, Benureau Y, et al. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS pathogens. 2021;17(4):e1009526.
    5. Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6(62).
    6. Badio M, Lhomme E, Kieh M, Beavogui AH, Kennedy SB, Doumbia S, et al. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials. 2021;22(1):86.
    7. Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021;18(10):e1003813.
    8. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62).
    9. Bendib I, Beldi-Ferchiou A, Schlemmer F, Maitre B, Surenaud M, Hue S, et al. Functional Ex Vivo Testing of Alveolar Monocytes in Patients with Pneumonia-Related ARDS. Cells. 2021;10(12).
    10. Bendib I, Beldi-Ferchiou A, Schlemmer F, Surenaud M, Maitre B, Plonquet A, et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. Crit Care. 2021;25(1):23.
    11. Betton M, Livrozet M, Planas D, Fayol A, Monel B, Vedie B, et al. Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;73(6):e1337-e44.
    12. Bonsergent E, Grisard E, Buchrieser J, Schwartz O, Thery C, Lavieu G. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. Nature communications. 2021;12(1):1864.
    13. Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, et al. Syncytia formation by SARS-CoV-2-infected cells. The EMBO journal. 2021;40(3):e107405.
    14. Capitaine L, Genuer R, Thiebaut R. Random forests for high-dimensional longitudinal data. Stat Methods Med Res. 2021;30(1):166-84.
    15. Cavarelli M, Hua S, Hantour N, Tricot S, Tchitchek N, Gommet C, et al. Leukocytospermia induces intraepithelial recruitment of dendritic cells and increases SIV replication in colorectal tissue explants. Commun Biol. 2021;4(1):861.
    16. Ceglia V, Kelley EJ, Boyle AS, Zurawski S, Mead HL, Harms CE, et al. A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires. Frontiers in immunology. 2021;12:735584.
    17. Ceglia V, Zurawski S, Montes M, Bouteau A, Wang Z, Ellis J, et al. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties. Journal of immunology. 2021.
    18. Cheng L, Li G, Pellegry CM, Yasui F, Li F, Zurawski SM, et al. TLR9- and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction via pDC-Dependent Mechanisms in Humanized Mice. Frontiers in immunology. 2021;12:672143.
    19. Colas C, Hejblum B, Rouillon S, thiebaut R, Oudeyer PY, Moulin-Frier C, et al. EpidemiOptim: A Toolbox for the Optimization of Control Policies in Epidemiological Models. Journal of Artificial Intelligence Research. 2021;71:479-519.
    20. Diallo MSK, Ayouba A, Keita AK, Thaurignac G, Sow MS, Kpamou C, et al. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. The Lancet Microbe. 2021;2(12):e676-e84.
    21. Diallo MSK, Toure A, Sow MS, Kpamou C, Keita AK, Taverne B, et al. Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;73(12):2166-74.
    22. Doring M, De Azevedo K, Blanco-Rodriguez G, Nadalin F, Satoh T, Gentili M, et al. Single-cell analysis reveals divergent responses of human dendritic cells to the MVA vaccine. Sci Signal. 2021;14(697).
    23. Dufloo J, Grzelak L, Staropoli I, Madec Y, Tondeur L, Anna F, et al. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. Cell Rep Med. 2021;2(5):100275.
    24. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med. 2021.
    25. Fenwick C, Turelli P, Perez L, Pellaton C, Esteves-Leuenberger L, Farina A, et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell reports. 2021;37(2):109814.
    26. Feraoun Y, Palgen JL, Joly C, Tchitchek N, Marcos-Lopez E, Dereuddre-Bosquet N, et al. The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications. Frontiers in immunology. 2021;12:784813.
    27. Fontanet A, Tondeur L, Grant R, Temmam S, Madec Y, Bigot T, et al. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Euro Surveill. 2021;26(15).
    28. Francis-Oliviero F, Bozoki S, Micsik A, Kieny MP, Lelievre JD. Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination). Vaccine. 2021;39(44):6539-44.
    29. Frith K, Munier CML, Hastings L, Mowat D, Wilson M, Seddiki N, et al. The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowat-Wilson Syndrome. Int J Mol Sci. 2021;22(10).
    30. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:103561.
    31. Galmiche S, Bruel T, Madec Y, Tondeur L, Grzelak L, Staropoli I, et al. Characteristics Associated with Olfactory and Taste Disorders in COVID-19. Neuroepidemiology. 2021;55(5):381-6.
    32. Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard E, et al. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. Fundam Clin Pharmacol. 2021;35(6):1141-58.
    33. Goldberg BS, Kaku CI, Dufloo J, Bruel T, Schwartz O, Spencer DA, et al. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity. mBio. 2021;12(5):e0174321.
    34. Isaric Clinical Characterisation Group. The value of open-source clinical science in pandemic response: lessons from ISARIC. Lancet Infect Dis. 2021;21(12):1623-4.
    35. Isaric Clinical Characterisation Group. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection. 2021;49(5):889-905.
    36. Mocorsep Study Group. Monocyte distribution width as a biomarker of resistance to corticosteroids in patients with sepsis: the MOCORSEP observational study. Intensive Care Med. 2021;47(10):1161-4.
    37. Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of infectious diseases. 2021;224(6):983-8.
    38. Kerneis S, Planas D, Imbeaud S, Staropoli I, Puech J, Robillard N, et al. Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual. Open Forum Infect Dis. 2021;8(8):ofab369.
    39. Kervevan J, Bouteau A, Lanza JS, Hammoudi A, Zurawski S, Surenaud M, et al. Targeting human langerin promotes HIV-1 specific humoral immune responses. PLoS pathogens. 2021;17(7):e1009749.
    40. Lesage S, Chazal M, Beauclair G, Batalie D, Cerboni S, Couderc E, et al. Discovery of Genes that Modulate Flavivirus Replication in an Interferon-Dependent Manner. J Mol Biol. 2021:167277.
    41. Levy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, et al. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. Journal of virology. 2021;95(9).
    42. Levy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surenaud M, et al. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. iScience. 2021;24(7):102711.
    43. Lin L, Hejblum BP. Bayesian mixture models for cytometry data analysis. WIREs Computational Statistics. 2021;13(4):e1535.
    44. Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay JY, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nature medicine. 2021;27(8):1319-21.
    45. Luo X, Mouquet H, Schwartz O, Greene WC. Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission. J Biol Chem. 2021;297(4):101098.
    46. Marlin R, Godot V, Cardinaud S, Galhaut M, Coleon S, Zurawski S, et al. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature communications. 2021;12(1):5215.
    47. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nature communications. 2021;12(1):844.
    48. Martinat C, Cormier A, Tobaly-Tapiero J, Palmic N, Casartelli N, Mahboubi B, et al. SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells. Nature communications. 2021;12(1):4582.
    49. Monel B, Planas D, Grzelak L, Smith N, Robillard N, Staropoli I, et al. Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. EBioMedicine. 2021;73:103637.
    50. Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, et al. Kinetics of the SARS-CoV-2 antibody response and serological estimation of time since infection. The Journal of infectious diseases. 2021.
    51. Perreau M, Suffiotti M, Marques-Vidal P, Wiedemann A, Levy Y, Laouenan C, et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nature communications. 2021;12(1):4888.
    52. Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature medicine. 2021;27(5):917-24.
    53. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-80.
    54. Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021;21(4):493-506.
    55. Rajah MM, Bernier A, Buchrieser J, Schwartz O. The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. J Mol Biol. 2021:167280.
    56. Rajah MM, Hubert M, Bishop E, Saunders N, Robinot R, Grzelak L, et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. The EMBO journal. 2021;40(24):e108944.
    57. Robinot R, Hubert M, de Melo GD, Lazarini F, Bruel T, Smith N, et al. SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. Nature communications. 2021;12(1):4354.
    58. Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe. 2021;2(2):e60-e9.
    59. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Frontiers in immunology. 2021;12:645210.
    60. Safder T, McCullough PA, Wheelan KR, Rahimi G, Zurawski S, Zurawski G, et al. Screening for SARS-CoV-2 via PCR and serological testing in asymptomatic healthcare workers. Proc (Bayl Univ Med Cent). 2021;34(4):437-41.
    61. Seddiki N, French M. COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire. Frontiers in immunology. 2021;12:649567.
    62. Seddiki N, Zaunders J, Phetsouphanh C, Brezar V, Xu Y, McGuire HM, et al. CD73(+) CD127(high) Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. Int J Mol Sci. 2021;22(2).
    63. Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184(5):1201-13 e14.
    64. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577).
    65. Temime L, Gustin MP, Duval A, Buetti N, Crepey P, Guillemot D, et al. A Conceptual Discussion About the Basic Reproduction Number of Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;72(1):141-3.
    66. Tu WJ, McCuaig RD, Melino M, Rawle DJ, Le TT, Yan K, et al. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discov. 2021;7(1):37.
    67. Wagstaffe HR, Susannini G, Thiebaut R, Richert L, Levy Y, Bockstal V, et al. Durable natural killer cell responses after heterologous two-dose Ebola vaccination. NPJ Vaccines. 2021;6(1):19.
    68. Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, et al. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Sci Adv. 2021;7(34).
  • 2020
    1. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370(6515).
    2. Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum BP, Durand M, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nature communications. 2020;11(1):3730.
    3. Tu WJ, McCuaig RD, Tan AHY, Hardy K, Seddiki N, Ali S, et al. Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. Frontiers in immunology. 2020;11:1228.
    4. Staropoli I, Dufloo J, Ducher A, Commere PH, Sartori-Rupp A, Novault S, et al. Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5. Journal of virology. 2020;94(6).
    5. Seddiki N, Picard F, Dupaty L, Levy Y, Godot V. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. 2020;8(3).
    6. Protiere C, Fressard L, Mora M, Meyer L, Preau M, Suzan-Monti M, et al. Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study. Vaccines. 2020;8(2).
    7. Protiere C, Fiorentino M, Sow A, Preau M, Mora M, Fressard L, et al. Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption? Aids. 2020;34(7):1095-9.
    8. Protiere C, Arnold M, Fiorentino M, Fressard L, Lelievre JD, Mimi M, et al. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment. J Int AIDS Soc. 2020;23(2):e25443.
    9. Palgen JL, Tchitchek N, Rodriguez-Pozo A, Jouhault Q, Abdelhouahab H, Dereuddre-Bosquet N, et al. Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. NPJ Vaccines. 2020;5:24.
    10. Orvain C, Lin YL, Jean-Louis F, Hocini H, Hersant B, Bennasser Y, et al. Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa. The Journal of clinical investigation. 2020;130(7):3777-90.
    11. Lhomme E, Hejblum BP, Lacabaratz C, Wiedemann A, Lelievre JD, Levy Y, et al. Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. Journal of immunological methods. 2020;477:112711.
    12. Levy Y, Lelievre JD, Assoumou L, Aznar E, Pulido F, Tambussi G, et al. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. Ann Intern Med. 2020;172(5):297-305.
    13. Levy Y, Lacabaratz C, Ellefsen-Lavoie K, Stohr W, Lelievre JD, Bart PA, et al. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS pathogens. 2020;16(6):e1008522.
    14. Jurado S, Moog C, Cano-Munoz M, Schmidt S, Laumond G, Ruocco V, et al. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors. J Mol Biol. 2020;432(20):5577-92.
    15. Hue S, Beldi-Ferchiou A, Bendib I, Surenaud M, Fourati S, Frapard T, et al. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020;202(11):1509-19.
    16. Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, et al. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
    17. Hellert J, Buchrieser J, Larrous F, Minola A, de Melo GD, Soriaga L, et al. Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. Nature communications. 2020;11(1):596.
    18. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12(559).
    19. Godot V, Tcherakian C, Gil L, Cervera-Marzal I, Li G, Cheng L, et al. TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. PLoS pathogens. 2020;16(11):e1009025.
    20. Gauthier M, Agniel D, Thiebaut R, Hejblum BP. dearseq: a variance component score test for RNA-seq differential analysis that effectively controls the false discovery rate. NAR Genom Bioinform. 2020;2(4):lqaa093.
    21. Fourati S, Hue S, Pawlotsky JM, Mekontso-Dessap A, de Prost N. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 2020;46(9):1781-3.
    22. Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine. 2020;59:102915.
    23. Ellouze M, Vigouroux L, Tcherakian C, Woerther PL, Guguin A, Robert O, et al. Overexpression of GILZ in macrophages limits systemic inflammation while increasing bacterial clearance in sepsis in mice. European journal of immunology. 2020;50(4):589-602.
    24. Dufloo J, Guivel-Benhassine F, Buchrieser J, Lorin V, Grzelak L, Dupouy E, et al. Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells. EMBO reports. 2020;21(2):e49351.
    25. Cook L, Munier CML, Seddiki N, Hardy MY, Anderson RP, Zaunders J, et al. Circulating gluten-specific, but not CMV-specific, CD39(+) regulatory T cells have an oligoclonal TCR repertoire. Clin Transl Immunology. 2020;9(1):e1096.
    26. Cocozza F, Nevo N, Piovesana E, Lahaye X, Buchrieser J, Schwartz O, et al. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus. J Extracell Vesicles. 2020;10(2):e12050.
    27. Carapito R, Mayr L, Molitor A, Verniquet M, Schmidt S, Tahar O, et al. A FcRIIa polymorphism has a HLA-B57 and HLA-B27 independent effect on HIV disease outcome. Genes Immun. 2020;21(4):263-268.
    28. Bouadma L, Wiedemann A, Patrier J, Surenaud M, Wicky PH, Foucat E, et al. Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. J Clin Immunol. 2020;40(8):1082-92.
    29. Boissady E, Kohlhauer M, Lidouren F, Hocini H, Lefebvre C, Chateau-Jouber S, et al. Ultrafast Hypothermia Selectively Mitigates the Early Humoral Response After Cardiac Arrest. J Am Heart Assoc. 2020;9(23):e017413.
    30. Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020;395(10221):384-8.
    31. Bekeredjian-Ding I, Van Molle W, Baay M, Neels P, speakers PEI, session c, et al. Human challenge trial workshop: Focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019. Biologicals. 2020;66:53-61.
    32. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
    33. Balelli I, Pasin C, Prague M, Crauste F, Effelterre TV, Bockstal V, et al. A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. J Theor Biol. 2020;495:110254.
  • 2019
    1. Zaunders J, Dyer WB, Churchill M, Munier CML, Cunningham PH, Suzuki K, et al. Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Delta32 heterozygous and HLA-B57 genotype. Journal of virus eradication. 2019;5(2):73-83.
    2. Villain L, Commenges D, Pasin C, Prague M, Thiebaut R. Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. Stat Med. 2019;38(2):221-35.
    3. Tissier R, Hocini H, Tchitchek N, Deye N, Legriel S, Pichon N, et al. Early blood transcriptomic signature predicts patients’ outcome after out-of-hospital cardiac arrest. 2019;138:222-32.
    4. Thiebaut R, Hejblum BP, Hocini H, Bonnabau H, Skinner J, Montes M, et al. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals. Frontiers in immunology. 2019;10:874.
    5. Surenaud M, Montes M, Lindestam Arlehamn CS, Sette A, Banchereau J, Palucka K, et al. Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination. PLoS pathogens. 2019;15(9):e1008011.
    6. Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, et al. Integrating Genomics into Healthcare: A Global Responsibility. Am J Hum Genet. 2019;104(1):13-20.
    7. Razazi K, Boissier F, Surenaud M, Bedet A, Seemann A, Carteaux G, et al. A multiplex analysis of sepsis mediators during human septic shock: a preliminary study on myocardial depression and organ failures. Ann Intensive Care. 2019;9(1):64.
    8. Planchais C, Kok A, Kanyavuz A, Lorin V, Bruel T, Guivel-Benhassine F, et al. HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells. Cell reports. 2019;27(2):572-85 e7.
    9. Pinto D, Fenwick C, Caillat C, Silacci C, Guseva S, Dehez F, et al. Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell host & microbe. 2019;26(5):623-37 e8.
    10. Perdiguero B, Gomez CE, Garcia-Arriaza J, Sanchez-Corzo C, Sorzano COS, Wilmschen S, et al. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Frontiers in immunology. 2019;10:2941.
    11. Pasin C, Balelli I, Van Effelterre T, Bockstal V, Solforosi L, Prague M, et al. Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation. Journal of virology. 2019;93(18).
    12. Palich R, Ghosn J, Chaillon A, Boilet V, Nere ML, Chaix ML, et al. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. Aids. 2019;33(2):279-84.
    13. Palgen JL, Tchitchek N, Huot N, Elhmouzi-Younes J, Lefebvre C, Rosenbaum P, et al. NK cell immune responses differ after prime and boost vaccination. J Leukoc Biol. 2019;105(5):1055-73.
    14. Moore CL, Stohr W, Crook AM, Richert L, Lelievre JD, Pantaleo G, et al. Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV. 2019;6(5):e334-e40.
    15. Matignon M, Lelievre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, et al. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS) 153 TREVE trial. HIV Med. 2019;20(3):202-13.
    16. Masse-Ranson G, Dusseaux M, Fiquet O, Darche S, Boussand M, Li Y, et al. Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice. European journal of immunology. 2019;49(6):954-65.
    17. Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Lefebvre C, Hocini H, et al. Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae. Frontiers in immunology. 2019;10:430.
    18. Lhomme E, Modet C, Augier A, Faye S, Dabakuyo-Yonli TS, Levy-Marchal C, et al. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context. Trials. 2019;20(1):422.
    19. Lelievre JD, Hocqueloux L. Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate. The Journal of infectious diseases. 2019;220(Supplement_1):S5-S6.
    20. Lelievre JD. Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption. The Journal of infectious diseases. 2019;220(Supplement_1):S16-S8.
    21. Jurado S, Cano-Munoz M, Morel B, Standoli S, Santarossa E, Moog C, et al. Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins. J Mol Biol. 2019;431(17):3091-106.
    22. Hocini H, Bonnabau H, Lacabaratz C, Lefebvre C, Tisserand P, Foucat E, et al. HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of virology. 2019;93(10).
    23. Hejblum BP, Alkhassim C, Gottardo R, Caron F, Thiebaut R. Sequential dirichlet process mixtures of multivariate SKEW t-Distributions for model-based clustering of flow cytometry data. The Annals of Applied Statistics. 2019;13(1):638-60.
    24. Hani L, Chaillon A, Nere ML, Ruffin N, Alameddine J, Salmona M, et al. Proliferative memory SAMHD1low CD4+ T cells harbour high levels of HIV-1 with compartmentalized viral populations. PLoS pathogens. 2019;15(6):e1007868.
    25. Gratia M, Rodero MP, Conrad C, Bou Samra E, Maurin M, Rice GI, et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS. The Journal of experimental medicine. 2019;216(5):1199-213.
    26. Gentili M, Lahaye X, Nadalin F, Nader GPF, Puig Lombardi E, Herve S, et al. The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. Cell reports. 2019;26(9):2377-93 e13.
    27. Fovet CM, Stimmer L, Contreras V, Horellou P, Hubert A, Seddiki N, et al. Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaques. EBioMedicine. 2019;47:492-505.
    28. Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, et al. Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. The Journal of infectious diseases. 2019;219(1):89-100.
    29. Fastenackels S, Bayard C, Larsen M, Magnier P, Bonnafous P, Seddiki N, et al. Phenotypic and Functional Differences between Human Herpesvirus 6- and Human Cytomegalovirus-Specific T Cells. Journal of virology. 2019;93(13).
    30. Durier C, Desaint C, Lelievre JD, Silbermann B, Pialoux G, Cuzin L, et al. Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials: a French cohort study. Aids. 2019;33(13):2061-2071.
    31. Diallo MSK, Rabilloud M, Ayouba A, Toure A, Thaurignac G, Keita AK, et al. Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study. Lancet Infect Dis. 2019;19(3):308-16.
    32. Buchrieser J, Degrelle SA, Couderc T, Nevers Q, Disson O, Manet C, et al. IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise. Science. 2019;365(6449):176-80.
    33. Bruel T, Schwartz O. HIV-1 Envelope FRETted Over by Antibodies. Cell host & microbe. 2019;25(6):767-8.
    34. Bouteau A, Kervevan J, Su Q, Zurawski SM, Contreras V, Dereuddre-Bosquet N, et al. DC Subsets Regulate Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells. Frontiers in immunology. 2019;10:1134.
  • 2018
    1. Zhang X, Lu X, Moog C, Yuan L, Liu Z, Li Z, et al. KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in HLA-B Bw4 Homozygous Individuals. Frontiers in immunology. 2018;9:1855.
    2. Tricarico PM, Zupin L, Ottaviani G, Pacor S, Jean-Louis F, Boniotto M, et al. Photobiomodulation therapy promotes in vitro wound healing in nicastrin KO HaCaT cells. J Biophotonics. 2018;11(12):e201800174.
    3. Sutton M, Thiebaut R, Liquet B. Sparse partial least squares with group and subgroup structure. Stat Med. 2018;37(23):3338-56.
    4. Soret P, Avalos M, Wittkop L, Commenges D, Thiebaut R. Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors. BMC Med Res Methodol. 2018;18(1):159.
    5. Seddiki N, Levy Y. Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies. Current opinion in HIV and AIDS. 2018;13(2):119-27.
    6. Sawaki D, Czibik G, Pini M, Ternacle J, Suffee N, Mercedes R, et al. Visceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Production. Circulation. 2018;138(8):809-22.
    7. Saez-Cirion A, Manel N. Immune Responses to Retroviruses. Annu Rev Immunol. 2018;36:193-220.
    8. Rosenbaum P, Tchitchek N, Joly C, Stimmer L, Hocini H, Dereuddre-Bosquet N, et al. Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. Frontiers in immunology. 2018;9:870.
    9. Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, et al. Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC). AIDS Care. 2018;30(7):914-20.
    10. Ploquin MJ, Casrouge A, Madec Y, Noel N, Jacquelin B, Huot N, et al. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC(+) CD4(+) cell levels: a surrogate marker candidate of HIV-induced intestinal damage. J Int AIDS Soc. 2018;21(7):e25144.
    11. Platon L, Pejoski D, Gautreau G, Targat B, Le Grand R, Beignon AS, et al. A computational approach for phenotypic comparisons of cell populations in high-dimensional cytometry data. 2018;132:66-75.
    12. Planchais C, Hocqueloux L, Ibanez C, Gallien S, Copie C, Surenaud M, et al. Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals. Journal of immunology. 2018;200(10):3519-29.
    13. Pasin C, Dufour F, Villain L, Zhang H, Thiebaut R. Controlling IL-7 Injections in HIV-Infected Patients. Bull Math Biol. 2018;80(9):2349-77.
    14. Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, et al. Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Scientific reports. 2018;8(1):3087.
    15. Paillaud E, Bastuji-Garin S, Plonquet A, Foucat E, Fournier B, Boutin E, et al. Combined Plasma Elevation of CRP, Intestinal-Type Fatty Acid-Binding Protein (I-FABP), and sCD14 Identify Older Patients at High Risk for Health Care-Associated Infections. J Gerontol A Biol Sci Med Sci. 2018;73(2):211-7.
    16. Ollivier-Yaniv C. Recruitment and Engagement in Preventive Clinical Trials: Interdependencies and Mediation. Journal of acquired immune deficiency syndromes. 2018;79 Suppl 1:S3-S7.
    17. Noel N, Jacquelin B, Huot N, Goujard C, Lambotte O, Muller-Trutwin M. Interferon-associated therapies toward HIV control: The back and forth. Cytokine & growth factor reviews. 2018;40:99-112.
    18. Mougin F, Auber D, Bourqui R, Diallo G, Dutour I, Jouhet V, et al. Visualizing omics and clinical data: Which challenges for dealing with their variety? Methods. 2018;132:3-18.
    19. Masse-Ranson G, Mouquet H, Di Santo JP. Humanized mouse models to study pathophysiology and treatment of HIV infection. Current opinion in HIV and AIDS. 2018;13(2):143-51.
    20. Li Y, Masse-Ranson G, Garcia Z, Bruel T, Kok A, Strick-Marchand H, et al. A human immune system mouse model with robust lymph node development. Nat Methods. 2018;15(8):623-30.
    21. Levy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018;392(10149):787-90.
    22. Levy Y, Dabis F. Preface. Journal of acquired immune deficiency syndromes. 2018;79 Suppl 1:S1-S2.
    23. Lethimonnier F, Levy Y. Genomic medicine France 2025. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2018;29(4):783-4.
    24. Lelievre JD, Ollivier-Yaniv C. Interview With Jean-Daniel Lelievre, PU-PH, Head of the Research Clinic of the VRI (Vaccine Research Institute). Journal of acquired immune deficiency syndromes. 2018;79 Suppl 1:S8-S12.
    25. Lahaye X, Gentili M, Silvin A, Conrad C, Picard L, Jouve M, et al. NONO Detects the Nuclear HIV Capsid to Promote cGAS-Mediated Innate Immune Activation. Cell. 2018;175(2):488-501 e22.
    26. Joas S, Parrish EH, Gnanadurai CW, Lump E, Sturzel CM, Parrish NF, et al. Species-specific host factors rather than virus-intrinsic virulence determine primate lentiviral pathogenicity. Nature communications. 2018;9(1):1371.
    27. Huot N, Bosinger SE, Paiardini M, Reeves RK, Muller-Trutwin M. Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies. Frontiers in immunology. 2018;9:780.
    28. Hubert A, Seddiki N. Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines. Human vaccines & immunotherapeutics. 2018;14(6):1432-7.
    29. Henrich TJ, Lelievre JD. Progress towards obtaining an HIV cure: slow but sure. Current opinion in HIV and AIDS. 2018;13(5):381-2.
    30. Gross L, Lhomme E, Pasin C, Richert L, Thiebaut R. Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. Int J Infect Dis. 2018;74:83-96.
    31. Gauthier M, Canoui-Poitrine F, Guery E, Desvaux D, Hue S, Canaud G, et al. Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrol Dial Transplant. 2018;33(4):709-16.
    32. Flamar AL, Bonnabau H, Zurawski S, Lacabaratz C, Montes M, Richert L, et al. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. PloS one. 2018;13(11):e0207794.
    33. Dufloo J, Bruel T, Schwartz O. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies. Retrovirology. 2018;15(1):51.
    34. Ducloy C, Su B, Mayr L, Klingler J, Decoville T, Schmidt S, et al. HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies. Aids. 2018;32(10):1239-45.
    35. Commenges D, Alkhassim C, Gottardo R, Hejblum B, Thiebaut R. cytometree: A binary tree algorithm for automatic gating in cytometry analysis. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2018;93(11):1132-40.
    36. Cheng L, Wang Q, Li G, Banga R, Ma J, Yu H, et al. TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. The Journal of clinical investigation. 2018;128(10):4387-96.
    37. Bruel T, Schwartz O. Markers of the HIV-1 reservoir: facts and controversies. Current opinion in HIV and AIDS. 2018;13(5):383-8.
    38. Bhargava A, Lahaye X, Manel N. Let me in: Control of HIV nuclear entry at the nuclear envelope. Cytokine & growth factor reviews. 2018;40:59-67.
    39. Bendenoun M, Samri A, Avettand-Fenoel V, Cardinaud S, Descours B, Carcelain G, et al. What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. EBioMedicine. 2018;27:51-60.
    40. Ayllon-Benitez A, Mougin F, Allali J, Thiebaut R, Thebault P. A new method for evaluating the impacts of semantic similarity measures on the annotation of gene sets. PloS one. 2018;13(11):e0208037.
    41. Alaoui L, Palomino G, Zurawski S, Zurawski G, Coindre S, Dereuddre-Bosquet N, et al. Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs. Cell Mol Life Sci. 2018;75(10):1871-87.
  • 2017
    1. Zurawski G, Shen X, Zurawski S, Tomaras GD, Montefiori DC, Roederer M, et al. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Journal of virology. 2017;91(9).
    2. Tu WJ, Hardy K, Sutton CR, McCuaig R, Li J, Dunn J, et al. Priming of transcriptional memory responses via the chromatin accessibility landscape in T cells. Scientific reports. 2017;7:44825.
    3. Todorova B, Salabert N, Tricot S, Boisgard R, Rathaux M, Le Grand R, et al. Fibered Confocal Fluorescence Microscopy for the Noninvasive Imaging of Langerhans Cells in Macaques. Contrast Media Mol Imaging. 2017;2017:3127908.
    4. Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Scientific reports. 2017;7(1):4122.
    5. Thiebaut R, Hue S, Le Marec F, Lelievre JD, Dupon M, Foucat E, et al. Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. 2017;31(17):2355-65.
    6. Ternacle J, Wan F, Sawaki D, Surenaud M, Pini M, Mercedes R, et al. Short-term high-fat diet compromises myocardial function: a radial strain rate imaging study. Eur Heart J Cardiovasc Imaging. 2017;18(11):1283-91.
    7. Surenaud M, Lacabaratz C, Zurawski G, Levy Y, Lelievre JD. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines. Expert Rev Vaccines. 2017;16(10):955-72.
    8. Subtil F, Delaunay C, Keita AK, Sow MS, Toure A, Leroy S, et al. Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;64(12):1788-90.
    9. Silvin A, Yu CI, Lahaye X, Imperatore F, Brault JB, Cardinaud S, et al. Constitutive resistance to viral infection in human CD141+ dendritic cells. Sci Immunol. 2017;2(13).
    10. Shi G, Schwartz O, Compton AA. More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins. Retrovirology. 2017;14(1):53.
    11. Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, et al. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell reports. 2017;21(13):3681-90.
    12. Ruffin N, Hani L, Seddiki N. From dendritic cells to B cells dysfunctions during HIV-1 infection: T follicular helper cells at the crossroads. Immunology. 2017;151(2):137-45.
    13. Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, et al. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell reports. 2017;20(9):2251-61.
    14. Prague M, Commenges D, Gran JM, Ledergerber B, Young J, Furrer H, et al. Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. Biometrics. 2017;73(1):294-304.
    15. Picat MQ, Pellegrin I, Bitard J, Wittkop L, Proust-Lima C, Liquet B, et al. Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PloS one. 2017;12(1):e0169164.
    16. Passaes CP, Bruel T, Decalf J, David A, Angin M, Monceaux V, et al. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents. Journal of virology. 2017;91(6).
    17. Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, et al. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol. 2017;140(6):1754-7 e6.
    18. Nikolova M, Wiedemann A, Lacabaratz C, Levy Y. [Deficiency of HIV-specific T cell responses: are the Treg guilty?]. Medecine sciences : M/S. 2017;33(8-9):723-6.
    19. Mouquet H. Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies? Immunity. 2017;46(4):527-9.
    20. Mayr LM, Su B, Moog C. Non-Neutralizing Antibodies Directed against HIV and Their Functions. Frontiers in immunology. 2017;8:1590.
    21. Mayr LM, Decoville T, Schmidt S, Laumond G, Klingler J, Ducloy C, et al. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. Scientific reports. 2017;7(1):12655.
    22. Mayr L, Su B, Moog C. Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals. Current opinion in HIV and AIDS. 2017;12(3):209-15.
    23. Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Hocini H, Benjelloun F, et al. Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry. Journal of immunology. 2017;199(5):1923-32.
    24. Lorin V, Malbec M, Eden C, Bruel T, Porrot F, Seaman MS, et al. Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. Mucosal immunology. 2017;10(3):814-26.
    25. Keita MM, Taverne B, Sy Savane S, March L, Doukoure M, Sow MS, et al. Depressive symptoms among survivors of Ebola virus disease in Conakry (Guinea): preliminary results of the PostEboGui cohort. BMC Psychiatry. 2017;17(1):127.
    26. Keita AK, Toure A, Sow MS, Raoul H, Magassouba N, Delaporte E, et al. Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017;23(6):412-3.
    27. Jarne A, Commenges D, Villain L, Prague M, Levy Y, Thiebaut R. Modeling Cd4(+) T Cells Dynamics in Hiv-Infected Patients Receiving Repeated Cycles of Exogenous Interleukin 7. Ann Appl Stat. 2017;11(3):1593-616.
    28. Huot N, Jacquelin B, Garcia-Tellez T, Rascle P, Ploquin MJ, Madec Y, et al. Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys. Nature medicine. 2017;23(11):1277-86.
    29. Hereth-Hebert E, Bah MO, Etard JF, Sow MS, Resnikoff S, Fardeau C, et al. Ocular Complications in Survivors of the Ebola Outbreak in Guinea. Am J Ophthalmol. 2017;175:114-21.
    30. Graham JP, Authie P, Karolina Palucka A, Zurawski G. Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine. Vaccine. 2017;35(35 Pt B):4532-9.
    31. Gautreau G, Pejoski D, Le Grand R, Cosma A, Beignon AS, Tchitchek N. SPADEVizR: an R package for visualization, analysis and integration of SPADE results. Bioinformatics. 2017;33(5):779-81.
    32. Etard JF, Sow MS, Leroy S, Toure A, Taverne B, Keita AK, et al. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis. 2017;17(5):545-52.
    33. Elhmouzi-Younes J, Palgen JL, Tchitchek N, Delandre S, Namet I, Bodinham CL, et al. In depth comparative phenotyping of blood innate myeloid leukocytes from healthy humans and macaques using mass cytometry. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2017;91(10):969-82.
    34. Dubourg G, Surenaud M, Levy Y, Hue S, Raoult D. Microbiome of HIV-infected people. Microbial pathogenesis. 2017;106:85-93.
    35. Donahue DA, Porrot F, Couespel N, Schwartz O. SUN2 Silencing Impairs CD4 T Cell Proliferation and Alters Sensitivity to HIV-1 Infection Independently of Cyclophilin A. Journal of virology. 2017;91(6).
    36. Descours B, Petitjean G, Lopez-Zaragoza JL, Bruel T, Raffel R, Psomas C, et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature. 2017;543(7646):564-7.
    37. Cook L, Munier CML, Seddiki N, van Bockel D, Ontiveros N, Hardy MY, et al. Circulating gluten-specific FOXP3(+)CD39(+) regulatory T cells have impaired suppressive function in patients with celiac disease. J Allergy Clin Immunol. 2017;140(6):1592-603 e8.
    38. Compton AA, Schwartz O. They Might Be Giants: Does Syncytium Formation Sink or Spread HIV Infection? PLoS pathogens. 2017;13(2):e1006099.
    39. Cheng L, Zhang Z, Li G, Li F, Wang L, Zhang L, et al. Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system. 2017;35(45):6143-53.
    40. Chauveau L, Donahue DA, Monel B, Porrot F, Bruel T, Richard L, et al. HIV fusion in Dendritic cells mainly occurs at the surface and is limited by low CD4 levels. Journal of virology. 2017;91:21.
    41. Cerboni S, Jeremiah N, Gentili M, Gehrmann U, Conrad C, Stolzenberg MC, et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. The Journal of experimental medicine. 2017;214(6):1769-85.
    42. Cardinaud S, Urrutia A, Rouers A, Coulon PG, Kervevan J, Richetta C, et al. Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. European journal of immunology. 2017;47(5):818-29.
    43. Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, et al. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. Journal of virology. 2017;91(8).
    44. Brezar V, Hani L, Surenaud M, Hubert A, Lacabaratz C, Lelievre JD, et al. Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine. PLoS pathogens. 2017;13(7):e1006489.
    45. Ayouba A, Toure A, Butel C, Keita AK, Binetruy F, Sow MS, et al. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. J Clin Microbiol. 2017;55(1):165-76.
    46. Agniel D, Hejblum BP. Variance component score test for time-course gene set analysis of longitudinal RNA-seq data. Biostatistics. 2017;18(4):589-604.
  • 2016
    • Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD, et al. Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PloS one. 2016;11(4):e0153484.
    • Zaunders J, Danta M, Bailey M, Mak G, Marks K, Seddiki N, et al. CD4+ T Follicular Helper and IgA+ B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals. Frontiers in immunology. 2016;7:438.
    • Viard JP, Assuied A, Levy Y, Souberbielle JC, Thiebaut R, Carrat F, et al. No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PloS one. 2016;11(12):e0168640.
    • Thiebaut R, Levy Y. Reply to Bordoni et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(12):1684-5.
    • Thiebaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, et al. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(9):1178-85.
    • Surenaud M, Manier C, Richert L, Thiebaut R, Levy Y, Hue S, et al. Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. BMC Immunol. 2016;17(1):44.
    • Sow MS, Etard JF, Baize S, Magassouba N, Faye O, Msellati P, et al. New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. The Journal of infectious diseases. 2016;214(10):1475-6.
    • Salabert N, Todorova B, Martinon F, Boisgard R, Zurawski G, Zurawski S, et al. Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. European journal of immunology. 2016;46(3):689-700.
    • Sagoo P, Garcia Z, Breart B, Lemaitre F, Michonneau D, Albert ML, et al. In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Nature medicine. 2016;22(1):64-71.
    • Rokx C, Vella S, Pantaleo G, Levy Y, Boucher CA. Unite forces to validate biomarkers in the quest for lasting HIV remission. Aids. 2016;30(11):1859-60.
    • Quillay H, El Costa H, Duriez M, Marlin R, Cannou C, Madec Y, et al. NK cells control HIV-1 infection of macrophages through soluble factors and cellular contacts in the human decidua. Retrovirology. 2016;13(1):39.
    • Pejoski D, Tchitchek N, Rodriguez Pozo A, Elhmouzi-Younes J, Yousfi-Bogniaho R, Rogez-Kreuz C, et al. Identification of Vaccine-Altered Circulating B Cell Phenotypes Using Mass Cytometry and a Two-Step Clustering Analysis. Journal of immunology. 2016;196(11):4814-31.
    • Pantaleo G, Levy Y. Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change. Current opinion in HIV and AIDS. 2016;11(6):576-84.
    • Nikolova M, Wiedemann A, Muhtarova M, Achkova D, Lacabaratz C, Levy Y. Subset- and Antigen-Specific Effects of Treg on CD8+ T Cell Responses in Chronic HIV Infection. PLoS pathogens. 2016;12(11):e1005995.
    • Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, et al. P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. PLoS pathogens. 2016;12(4):e1005571.
    • Liquet B, de Micheaux PL, Hejblum BP, Thiebaut R. Group and sparse group partial least square approaches applied in genomics context. Bioinformatics. 2016;32(1):35-42.
    • Li J, Hardy K, Phetsouphanh C, Tu WJ, Sutcliffe EL, McCuaig R, et al. Nuclear PKC-theta facilitates rapid transcriptional responses in human memory CD4+ T cells through p65 and H2B phosphorylation. Journal of cell science. 2016;129(12):2448-61.
    • Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, et al. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PloS one. 2016;11(4):e0152952.
    • Lelievre JD, Levy Y. HIV-1 prophylactic vaccines: state of the art. Journal of virus eradication. 2016;2(1):5-11.
    • Le Grand R, Dereuddre-Bosquet N, Dispinseri S, Gosse L, Desjardins D, Shen X, et al. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Journal of virology. 2016;90(11):5315-28.
    • Lahouassa H, Blondot ML, Chauveau L, Chougui G, Morel M, Leduc M, et al. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(19):5311-6.
    • Lahaye X, Satoh T, Gentili M, Cerboni S, Silvin A, Conrad C, et al. Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell reports. 2016;15(4):879-92.
    • Keoshkerian E, Hunter M, Cameron B, Nguyen N, Sugden P, Bull R, et al. Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection. Journal of viral hepatitis. 2016;23(12):985-93.
    • Huot N, Rascle P, Garcia-Tellez T, Jacquelin B, Muller-Trutwin M. Innate immune cell responses in non pathogenic versus pathogenic SIV infections. Current opinion in virology. 2016;19:37-44.
    • Hotz C, Boniotto M, Guguin A, Surenaud M, Jean-Louis F, Tisserand P, et al. Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. The Journal of investigative dermatology. 2016;136(9):1768-80.
    • Garcia-Tellez T, Huot N, Ploquin MJ, Rascle P, Jacquelin B, Muller-Trutwin M. Non-human primates in HIV research: Achievements, limits and alternatives. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016;46:324-332.
    • El Costa H, Quillay H, Marlin R, Cannou C, Duriez M, Benjelloun F, et al. The local environment orchestrates mucosal decidual macrophage differentiation and substantially inhibits HIV-1 replication. Mucosal immunology. 2016;9(3):634-46.
    • Dubourg G, Lagier JC, Hue S, Surenaud M, Bachar D, Robert C, et al. Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen. BMJ open gastroenterology. 2016;3(1):e000080.
    • Donahue DA, Schwartz O. Actin’ on HIV: How Dendritic Cells Spread Infection. Cell host & microbe. 2016;19(3):267-9.
    • Donahue DA, Amraoui S, di Nunzio F, Kieffer C, Porrot F, Opp S, et al. SUN2 Overexpression Deforms Nuclear Shape and Inhibits HIV. Journal of virology. 2016;90(8):4199-214.
    • Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO reports. 2016;17(11):1657-71.
    • Bruel T, Mouquet H, Schwartz O. [Antibodies that kill HIV-1-infected cells]. Medecine sciences : M/S. 2016;32(8-9):671-4.
    • Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nature communications. 2016;7:10844.
    • Brezar V, Godot V, Cheng L, Su L, Levy Y, Seddiki N. T-Regulatory Cells and Vaccination “Pay Attention and Do Not Neglect Them”: Lessons from HIV and Cancer Vaccine Trials. Vaccines. 2016;4(3).
    • Bodez D, Hocini H, Tchitchek N, Tisserand P, Benhaiem N, Barau C, et al. Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study. PloS one. 2016;11(11):e0167213.
  • 2015
    • Tricot S, Meyrand M, Sammicheli C, Elhmouzi-Younes J, Corneau A, Bertholet S, et al. Evaluating the efficiency of isotope transmission for improved panel design and a comparison of the detection sensitivities of mass cytometer instruments. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2015 Apr;87(4):357-68. PubMed PMID: 25704858. Epub 2015/02/24. eng.
    • Su B, Peressin M, Moog C. Inhibition of HIV-1 Spread: Cell-Free Versus Cell-Cell. In: Hope JT, Stevenson M, Richman D, editors. Encyclopedia of AIDS. New York, NY: Springer New York; 2015. p. 1-13.
    • Su B, Peressin M, Ducloy C, Penichon J, Mayr LM, Laumond G, et al. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection. AIDS research and human retroviruses. 2015 Nov;31(11):1187-91. PubMed PMID: 26252799.
    • Silvin A, Manel N. Innate immune sensing of HIV infection. Current opinion in immunology. 2015 Feb;32:54-60. PubMed PMID: 25617674.
    • Ruffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, van Lunzen J, et al. Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1. Aids. 2015 Mar 13;29(5):519-30. PubMed PMID: 25715102. Pubmed Central PMCID: 4342413.
    • Roesch F, Richard L, Rua R, Porrot F, Casartelli N, Schwartz O. Vpr Enhances Tumor Necrosis Factor Production by HIV-1- Infected T Cells. Journal of virology. 2015 Dec 1;89(23):12118-30. PubMed PMID: 26401039. Pubmed Central PMCID: 4645299.
    • Richert L, Lhomme E, Fagard C, Levy Y, Chene G, Thiebaut R. Recent developments in clinical trial designs for HIV vaccine research. Human vaccines & immunotherapeutics. 2015;11(4):1022-9. PubMed PMID: 25751670.
    • Quillay H, El Costa H, Marlin R, Duriez M, Cannou C, Chretien F, et al. Distinct characteristics of endometrial and decidual macrophages and regulation of their permissivity to HIV-1 infection by SAMHD1. Journal of virology. 2015 Jan 15;89(2):1329-39. PubMed PMID: 25392215. Pubmed Central PMCID: 4300664.
    • Pepin A, Biola-Vidamment A, Latre de Late P, Espinasse MA, Godot V, Pallardy M. [TSC-22D proteins: new regulators of cell homeostasis?]. Medecine sciences : M/S. 2015 Jan;31(1):75-83. PubMed PMID: 25658734. Les proteines de la famille TSC-22D – De nouveaux regulateurs de l'homeostasie cellulaire ?
    • Moreno-Nieves UY, Didier C, Levy Y, Barre-Sinoussi F, Scott-Algara D, Network AHV. S100A9 Tetramers, Which are Ligands of CD85j, Increase the Ability of MVAHIV-Primed NK Cells to Control HIV Infection. Frontiers in immunology. 2015;6:478. PubMed PMID: 26441983. Pubmed Central PMCID: 4585218.
    • Lahaye X, Manel N. Viral and cellular mechanisms of the innate immune sensing of HIV. Current opinion in virology. 2015 Apr;11:55-62. PubMed PMID: 25697108.
    • Kok A, Hocqueloux L, Hocini H, Carriere M, Lefrou L, Guguin A, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal immunology. 2015 Jan;8(1):127-40. PubMed PMID: 24985081.
    • Kohlhauer M, Lidouren F, Remy-Jouet I, Mongardon N, Adam C, Bruneval P, et al. Hypothermic Total Liquid Ventilation Is Highly Protective Through Cerebral Hemodynamic Preservation and Sepsis-Like Mitigation After Asphyxial Cardiac Arrest. Critical care medicine. 2015 Oct;43(10):e420-30. PubMed PMID: 26110489.
    • Joo H, Upchurch K, Zhang W, Ni L, Li D, Xue Y, et al. Opposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization. Journal of immunology. 2015 Aug 15;195(4):1723-31. PubMed PMID: 26123355. Pubmed Central PMCID: 4530104.
    • Hejblum BP, Skinner J, Thiebaut R. Time-Course Gene Set Analysis for Longitudinal Gene Expression Data. PLoS computational biology. 2015 Jun;11(6):e1004310. PubMed PMID: 26111374. Pubmed Central PMCID: 4482329.
    • Gentili M, Kowal J, Tkach M, Satoh T, Lahaye X, Conrad C, et al. Transmission of innate immune signaling by packaging of cGAMP in viral particles. Science. 2015 Sep 11;349(6253):1232-6. PubMed PMID: 26229115.
    • Flamar AL, Contreras V, Zurawski S, Montes M, Dereuddre-Bosquet N, Martinon F, et al. Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo. PloS one. 2015;10(9):e0135513. PubMed PMID: 26407317. Pubmed Central PMCID: 4583231.
    • Doussau A, Thiebaut R, Geoerger B, Schoffski P, Floquet A, Le Deley MC, et al. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 Feb;26(2):422-8. PubMed PMID: 25403589.
    • Dereuddre-Bosquet N, Baron ML, Contreras V, Gosse L, Mangeot I, Martinon F, et al. HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo- 5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. PubMed PMID: 25839103.
    • Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nature reviews Immunology. 2015 Jul;15(7):429-40. PubMed PMID: 26052098.
    • Colson P, Levy Y, Raoult D. Response to a Letter to the Editor by Joachim Denner on HIV infection en route to endogenization: two cases. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015 Apr;21(4):e35-7. PubMed PMID: 25595705.
    • Colineau L, Rouers A, Yamamoto T, Xu Y, Urrutia A, Pham HP, et al. HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. PloS one. 2015;10(10):e0140978. PubMed PMID: 26501424. Pubmed Central PMCID: 4621058.
    • Chauveau L, Puigdomenech I, Ayinde D, Roesch F, Porrot F, Bruni D, et al. HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells. Retrovirology. 2015;12:2. PubMed PMID: 25582927. Pubmed Central PMCID: 4307230.
    • Brezar V, Tu WJ, Seddiki N. PKC-Theta in Regulatory and Effector T-cell Functions. Frontiers in immunology. 2015;6:530. PubMed PMID: 26528291. Pubmed Central PMCID: 4602307.
    • Brezar V, Ruffin N, Richert L, Surenaud M, Lacabaratz C, Palucka K, et al. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS pathogens. 2015 Mar;11(3):e1004752. PubMed PMID: 25816350. Pubmed Central PMCID: 4376642.
    • Bet A, Maze EA, Bansal A, Sterrett S, Gross A, Graff-Dubois S, et al. The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology. 2015;12:15. PubMed PMID: 25809376. Pubmed Central PMCID: 4335690.
    • Ayinde D, Bruel T, Cardinaud S, Porrot F, Prado JG, Moris A, et al. SAMHD1 limits HIV-1 antigen presentation by monocyte-derived dendritic cells. Journal of virology. 2015 Apr 29. PubMed PMID: 25926647. Pubmed Central PMCID: 4473575.
    • Akinbobuyi B, Byrd MR, Chang CA, Nguyen M, Seifert ZJ, Flamar AL, et al. Facile syntheses of functionalized toll-like receptor 7 agonists. Tetrahedron letters. 2015 Jan 8;56(2):458-60. PubMed PMID: 25601818. Pubmed Central PMCID: 4296738.
    • Adam L, Rosenbaum P, Cosma A, Le Grand R, Martinon F. Identification of skin immune cells in non-human primates. Journal of immunological methods. 2015 Nov;426:42-9. PubMed PMID: 26219836.
  • 2014
    • Zaunders JJ, Levy Y, Seddiki N. Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses. Cytokine & growth factor reviews. 2014 Aug;25(4):391-401. PubMed PMID: 25130296.
    • Uchtenhagen H, Schiffner T, Bowles E, Heyndrickx L, LaBranche C, Applequist SE, et al. Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. Journal of immunology. 2014 Jun 15;192(12):5802-12. PubMed PMID: 24829409. Pubmed Central PMCID: 4112278.
    • Touzot M, Grandclaudon M, Cappuccio A, Satoh T, Martinez-Cingolani C, Servant N, et al. Combinatorial flexibility of cytokine function during human T helper cell differentiation. Nature communications. 2014;5:3987. PubMed PMID: 24865484.
    • Thiebaut R, Prague M, Commenges D. [Mathematical dynamical models for personalized medicine]. Medecine sciences : M/S. 2014 Nov;30 Spec No 2:23-6. PubMed PMID: 25407454. Modeles mathematiques dynamiques pour la medecine personnalisee.
    • Thiebaut R, Hejblum B, Richert L. [The analysis of "Big Data" in clinical research]. Revue d'epidemiologie et de sante publique. 2014 Feb;62(1):1-4. PubMed PMID: 24434249. L'analyse des "Big Data" en recherche clinique.
    • Thiebaut R, Drylewicz J, Prague M, Lacabaratz C, Beq S, Jarne A, et al. Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection. PLoS computational biology. 2014 May;10(5):e1003630. PubMed PMID: 24853554. Pubmed Central PMCID: 4031052.
    • Terrazzini N, Bajwa M, Vita S, Cheek E, Thomas D, Seddiki N, et al. A novel cytomegalovirus-induced regulatory-type T-cell subset increases in size during older life and links virus-specific immunity to vascular pathology. The Journal of infectious diseases. 2014 May 1;209(9):1382-92. PubMed PMID: 24203779. Pubmed Central PMCID: 3982844.
    • Su B, Lederle A, Laumond G, Ducloy C, Schmidt S, Decoville T, et al. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. Journal of virology. 2014 Sep;88(18):10975-81. PubMed PMID: 24965460. Pubmed Central PMCID: 4178849.
    • Su B, Biedma ME, Lederle A, Peressin M, Lambotin M, Proust A, et al. Dendritic cell- lymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV- 1 replication in dendritic cells. Journal of virology. 2014 May;88(9):5109-21. PubMed PMID: 24574390. Pubmed Central PMCID: 3993804.
    • Skinner JA, Zurawski SM, Sugimoto C, Vinet-Oliphant H, Vinod P, Xue Y, et al. Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment. Clinical and vaccine immunology : CVI. 2014 Dec;21(12):1668-80. PubMed PMID: 25298110. Pubmed Central PMCID: 4248778.
    • Sheik-Khalil E, Bray MA, Ozkaya Sahin G, Scarlatti G, Jansson M, Carpenter AE, et al. Automated image-based assay for evaluation of HIV neutralization and cell-to- cell fusion inhibition. BMC infectious diseases. 2014;14:472. PubMed PMID: 25176034. Pubmed Central PMCID: 4261578.
    • Sedger LM, Seddiki N, Ranasinghe C. Cytokines and cytokine receptors as immunotherapeutics: humble beginnings and exciting futures. Cytokine & growth factor reviews. 2014 Aug;25(4):351-3. PubMed PMID: 25189353.
    • Seddiki N, Kaufmann DE. Editorial overview: cell dysfunction and exhaustion in HIV infection. Current opinion in HIV and AIDS. 2014 Sep;9(5):437-8. PubMed PMID: 25023624. Pubmed Central PMCID: 4213930.
    • Seddiki N, Cook L, Hsu DC, Phetsouphanh C, Brown K, Xu Y, et al. Human antigen-specific CD4(+) CD25(+) CD134(+) CD39(+) T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses. European journal of immunology. 2014 Jun;44(6):1644-61. PubMed PMID: 24752698.
    • Seddiki N, Brezar V, Ruffin N, Levy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. 2014 May;142(1):32-8. PubMed PMID: 24303979. Pubmed Central PMCID: 3992045.
    • Seddiki N, Brezar V, Draenert R. Cell exhaustion in HIV-1 infection: role of suppressor cells. Current opinion in HIV and AIDS. 2014 Sep;9(5):452-8. PubMed PMID: 25010895.
    • Richert L, Doussau A, Lelievre JD, Arnold V, Rieux V, Bouakane A, et al. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials. 2014;15:68. PubMed PMID: 24571662. Pubmed Central PMCID: 3941694.
    • Phetsouphanh C, Xu Y, Bailey M, Pett S, Zaunders J, Seddiki N, et al. Ratios of effector to central memory antigen-specific CD4(+) T cells vary with antigen exposure in HIV+ patients. Immunology and cell biology. 2014 Apr;92(4):384-8. PubMed PMID: 24492798.
    • Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. The Journal of experimental medicine. 2014 Sep 22;211(10):2033-45. PubMed PMID: 25225461. Pubmed Central PMCID: 4172212.
    • Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, et al. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. Aids. 2014 Mar 13;28(5):667-77. PubMed PMID: 24451159.
    • Peressin M, Holl V, Moog C. [Anti-HIV antibodies: multiple antiviral activities]. Medecine sciences : M/S. 2014 Jan;30(1):69-75. PubMed PMID: 24472462. Les anticorps anti-VIH -de multiples activites antivirales.
    • Moroni M, Ghezzi S, Baroli P, Heltai S, De Battista D, Pensieroso S, et al. Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of translational medicine. 2014;12:335. PubMed PMID: 25477316. Pubmed Central PMCID: 4272524.
    • Moreno-Nieves UY, Didier C, Levy Y, Barre-Sinoussi F, Scott-Algara D, Network AHV. NK cells are primed by ANRS MVA(HIV)-infected DCs, via a mechanism involving NKG2D and membrane-bound IL-15, to control HIV-1 infection in CD4+ T cells. European journal of immunology. 2014 Aug;44(8):2370-9. PubMed PMID: 24777763.
    • Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal immunology. 2014 Jan;7(1):46-56. PubMed PMID: 23591718.
    • Malbec M, Mouquet H, Schwartz O. [HIV-1 cell-to- cell transmission and broadly neutralizing antibodies]. Medecine sciences : M/S. 2014 May;30(5):508-10. PubMed PMID: 24939535. Les anticorps anti-VIH- 1 et la transmission virale de cellule a cellule.
    • Levy Y, Thiebaut R, Montes M, Lacabaratz C, Sloan L, King B, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European journal of immunology. 2014 Sep;44(9):2802-10. PubMed PMID: 25042008.
    • Lederle A, Su B, Holl V, Penichon J, Schmidt S, Decoville T, et al. Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcgammaRIIa independent mechanism and do not diminish cytokines production. Scientific reports. 2014;4:5845. PubMed PMID: 25132382. Pubmed Central PMCID: 4135332.
    • Kim K, Perera R, Tan DB, Fernandez S, Seddiki N, Waring J, et al. Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Tuberculosis. 2014 Sep;94(5):494-501. PubMed PMID: 25095750.
    • Karaki S, Garcia G, Tcherakian C, Capel F, Tran T, Pallardy M, et al. Enhanced glucocorticoid-induced leucine zipper in dendritic cells induces allergen-specific regulatory CD4(+) T-cells in respiratory allergies. Allergy. 2014 May;69(5):624-31. PubMed PMID: 24606015.
    • Joo H, Li D, Dullaers M, Kim TW, Duluc D, Upchurch K, et al. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity. 2014 Oct 16;41(4):592-604. PubMed PMID: 25308333. Pubmed Central PMCID: 4221489.
    • Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. The Journal of clinical investigation. 2014 Dec;124(12):5516-20. PubMed PMID: 25401470. Pubmed Central PMCID: 4348945.
    • Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiebaut R, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2014 Jan 14;111(2):869-74. PubMed PMID: 24367114. Pubmed Central PMCID: 3896147.
    • Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, et al. Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1- uninfected adult participants. Clinical and vaccine immunology : CVI. 2014 Nov;21(11):1589-99. PubMed PMID: 25253665. Pubmed Central PMCID: 4248765.
    • Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, et al. Macrophage- and neutrophil-derived TNF-alpha instructs skin langerhans cells to prime antiviral immune responses. Journal of immunology. 2014 Sep 1;193(5):2416-26. PubMed PMID: 25057007. Pubmed Central PMCID: 4134993.
    • Duluc D, Joo H, Ni L, Yin W, Upchurch K, Li D, et al. Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. Journal of immunology. 2014 Jun 15;192(12):5776-88. PubMed PMID: 24835401. Pubmed Central PMCID: 4048825.
    • Duluc D, Banchereau R, Gannevat J, Thompson-Snipes L, Blanck JP, Zurawski S, et al. Transcriptional fingerprints of antigen-presenting cell subsets in the human vaginal mucosa and skin reflect tissue-specific immune microenvironments. Genome medicine. 2014;6(11):98. PubMed PMID: 25520755. Pubmed Central PMCID: 4268898.
    • Cummings JS, Moreno-Nieves UY, Arnold V, Gilbert A, Yarbrough K, Didier C, et al. Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVAHIV. Vaccine. 2014 Sep 29;32(43):5577-84. PubMed PMID: 25131736.
    • Crespillo S, Camara-Artigas A, Casares S, Morel B, Cobos ES, Mateo PL, et al. Single- chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV- 1 drugs. Proceedings of the National Academy of Sciences of the United States of America. 2014 Dec 23;111(51):18207-12. PubMed PMID: 25489108. Pubmed Central PMCID: 4280599.
    • Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell host & microbe. 2014 Dec 10;16(6):736-47. PubMed PMID: 25464829.
    • Colson P, Ravaux I, Tamalet C, Glazunova O, Baptiste E, Chabriere E, et al. HIV infection en route to endogenization: two cases. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014 Dec;20(12):1280-8. PubMed PMID: 25366539. Pubmed Central PMCID: 4360783.
    • Carriere M, Lacabaratz C, Kok A, Benne C, Jenabian MA, Casartelli N, et al. HIV "elite controllers" are characterized by a high frequency of memory CD8+ CD73+ T cells involved in the antigen-specific CD8+ T-cell response. The Journal of infectious diseases. 2014 May 1;209(9):1321-30. PubMed PMID: 24357632.
    • Calmette J, Ellouze M, Tran T, Karaki S, Ronin E, Capel F, et al. Glucocorticoid-induced leucine zipper enhanced expression in dendritic cells is sufficient to drive regulatory T cells expansion in vivo. Journal of immunology. 2014 Dec 15;193(12):5863-72. PubMed PMID: 25362183.
    • Brezar V, Ruffin N, Levy Y, Seddiki N. A highly relevant and efficient single step method for simultaneous depletion and isolation of human regulatory T cells in a clinical setting. Journal of immunological methods. 2014 Sep;411:70-5. PubMed PMID: 24925808.
    • Borges AH, Weitz JI, Collins G, Baker JV, Levy Y, Davey RT, Jr., et al. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral- treated HIV disease. Aids. 2014 Jul 31;28(12):1791-6. PubMed PMID: 25003720. Pubmed Central PMCID: 4499102.
    • Bernard-Stoecklin S, Gommet C, Cavarelli M, Le Grand R. Nonhuman primate models for cell-associated simian immunodeficiency virus transmission: the need to better understand the complexity of HIV mucosal transmission. The Journal of infectious diseases. 2014 Dec 15;210 Suppl 3:S660-6. PubMed PMID: 25414421.